Syros Pharmaceuticals Inc (NASDAQ:SYRS) released its quarterly earnings results on Monday. The company reported ($0.47) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.64) by $0.17.

Syros Pharmaceuticals (NASDAQ:SYRS) opened at 16.03 on Tuesday. The stock has a 50 day moving average price of $11.54 and a 200 day moving average price of $12.97. The company’s market cap is $374.78 million. Syros Pharmaceuticals has a 52 week low of $8.16 and a 52 week high of $21.50.

Several research firms recently weighed in on SYRS. Wedbush reissued an “outperform” rating and set a $18.00 price target (down from $22.00) on shares of Syros Pharmaceuticals in a report on Monday. Zacks Investment Research upgraded Syros Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Tuesday, December 6th. Cann restated a “buy” rating and set a $28.00 price objective on shares of Syros Pharmaceuticals in a research note on Tuesday, December 6th. Finally, Oppenheimer Holdings Inc. set a $28.00 price objective on Syros Pharmaceuticals and gave the stock a “buy” rating in a research note on Monday, February 27th. Two equities research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. The company presently has an average rating of “Buy” and a consensus target price of $21.00.

This article was originally published by and is the sole property of American Banking News. If you happen to be reading this article on another website, it was stolen and illegally republished in violation of U.S. and International copyright law. The original version of this story can be read at https://www.americanbankingnews.com/2017/03/21/syros-pharmaceuticals-inc-syrs-announces-earnings-results.html

An institutional investor recently raised its position in Syros Pharmaceuticals stock. State Street Corp boosted its stake in shares of Syros Pharmaceuticals Inc (NASDAQ:SYRS) by 81.9% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 45,447 shares of the company’s stock after buying an additional 20,468 shares during the period. State Street Corp owned approximately 0.19% of Syros Pharmaceuticals worth $554,000 as of its most recent SEC filing. 54.47% of the stock is owned by institutional investors and hedge funds.

Your IP Address:

Syros Pharmaceuticals Company Profile

Syros Pharmaceuticals, Inc is a biopharmaceutical company. The Company offers a gene control platform designed to analyze the unexploited region of deoxyribonucleic acid (DNA) in human disease tissue to identify and drug targets linked to genomically defined patient populations. The Company is focused on developing treatments for cancer and immune-mediated diseases and is building a pipeline of gene control medicines.

5 Day Chart for NASDAQ:SYRS

Receive News & Ratings for Syros Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syros Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.